XTLB supply chain intelligence for XTL Biopharmaceuticals Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
XTL Biopharmaceuticals Ltd. (XTLB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| THE-SOCIAL-PROXY | THE-SOCIAL-PROXY | 90% | In June 2024, we announced that we entered into a share purchase agreement with the shareholders of The Social Proxy |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from XTLB graph: t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuzum… |
| ABT | Abbott Laboratories | 72% | t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuzumab, being developed by Abbott Laboratories. In addition, in the future allogeneic… |
| INCR | InterCure Ltd. | 72% | Reciprocal relationship from INCR graph: Reciprocal relationship from XTLB graph: le assets 14 - 1,729 - Gain from sale of investment in associate - (1,051 ) - 561 1,695 - Changes in operating asset … |
| INCR | InterCure Ltd. | 72% | le assets 14 - 1,729 - Gain from sale of investment in associate - (1,051 ) - 561 1,695 - Changes in operating asset and liability items: Decrease (increase) in trade receivables 8 58 (50 ) 3 Decreas… |
| NCEL | NewcelX Ltd. | 72% | Reciprocal relationship from NCEL graph: oodwill Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We operate as … |
| NVSEF | Novartis AG | 72% | t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuzumab, being developed by Abbott Laboratories. In addition, in the future allogeneic… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from XTLB graph: t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuz… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BIOSSIL-INC | BIOSSIL-INC | 92% | In March 2025, we announced that we entered into an Exclusive Sublicense Agreement with Biossil Inc., a company incorporated under the laws of Canada |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from ABT graph: Reciprocal relationship from XTLB graph: t, being developed by Novartis AG, ar… |
| ABT | Abbott Laboratories | 72% | t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuzumab, being developed by Abbott Laboratories. In addition, in the future allogeneic… |
| ALAR | Alarum Technologies Ltd. | 72% | Reciprocal relationship from ALAR graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from ALAR graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from ALAR g… |
| ALAR | Alarum Technologies Ltd. | 72% | s The Proxy Social’s solution unlockable and transparent. Because these proxies are real Internet Protocol legitimate addresses from actual mobile devices (modems), they offer a level of flexibility … |
| CANF | Can-Fite BioPharma Ltd. | 72% | Reciprocal relationship from CANF graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from CANF graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from CANF g… |
| CANF | Can-Fite BioPharma Ltd. | 72% | ns or conditions. ● Accounting for business combination We allocate the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed, based upon their e… |
| INCR | InterCure Ltd. | 72% | Reciprocal relationship from INCR graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from INCR graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from INCR g… |
| INCR | InterCure Ltd. | 72% | le assets 14 - 1,729 - Gain from sale of investment in associate - (1,051 ) - 561 1,695 - Changes in operating asset and liability items: Decrease (increase) in trade receivables 8 58 (50 ) 3 Decreas… |
| NVSEF | Novartis AG | 72% | t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuzumab, being developed by Abbott Laboratories. In addition, in the future allogeneic… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from XTLB graph: t, being developed by Novartis AG, are being studied in combination with bortezomib for relapsed myeloma; and elotuz… |
| TATT | TAT Technologies Ltd. | 72% | Reciprocal relationship from TATT graph: Reciprocal relationship from XTLB graph: ns or conditions. ● Accounting for business combination We allocate the purchase price of acquired companies to the t… |
| TATT | TAT Technologies Ltd. | 72% | ns or conditions. ● Accounting for business combination We allocate the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed, based upon their e… |
| XAIR | Beyond Air, Inc. | 72% | Reciprocal relationship from XAIR graph: ,607 $ 1,950 $ 14,341 Non-controlling interest $ - $ 529 $ 229 $ 758 NOTE 12 – SUBSEQUENT EVENTS On January 8, 2026, XTL Biopharmaceuticals Ltd. (“XTL”) enter… |
| BRIGHT-DATA-LTD | BRIGHT-DATA-LTD | 62% | which we operate are characterized by intense competition, constant innovation and evolving security threats. We compete with companies that offer web data collection products. Our current and potent… |
| LINKEDIN-CORPORATION | LINKEDIN-CORPORATION | 62% | of our business and prospects may be materially and adversely affected, and the market price of our ADSs could decline. You should consider our prospects in light of the risks and uncertainties that … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| XTLB-DEBT | Debt stack $86,000 | 90% | Market cache reports total debt of $86,000. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| XTLB-OWNER-GAMMA-INVESTING-LLC | Gamma Investing LLC | 95% | 13F/ownership overlay lists Gamma Investing LLC; shares held 3,388; ownership 0.14%; value $12,061; as of 2026-03-31. |
| XTLB-OWNER-SMARTHARVEST-PORTFOLIOS-LLC | Smartharvest Portfolios, LLC | 95% | 13F/ownership overlay lists Smartharvest Portfolios, LLC; shares held 13,351; ownership 0.56%; value $47,529; as of 2026-03-31. |
| XTLB-OWNER-NOKED-ISRAEL-LTD | Noked Israel Ltd. | 95% | 13F/ownership overlay lists Noked Israel Ltd.; shares held 49,722; ownership 2.10%; value $177,010; as of 2025-12-31. |
| XTLB-OWNER-CITADEL-ADVISORS-LLC | Citadel Advisors Llc | 95% | 13F/ownership overlay lists Citadel Advisors Llc; shares held 18,967; ownership 0.80%; value $67,522; as of 2025-12-31. |
| XTLB-OWNER-XTX-TOPCO-LTD | Xtx Topco Ltd | 95% | 13F/ownership overlay lists Xtx Topco Ltd; shares held 2,560; ownership 0.11%; value $9,113; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| META | Meta Platforms, Inc. | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 1 | ['customer'] |
| TATT | TAT Technologies Ltd. | 100.00 | 1 | ['customer'] |
| INCR | InterCure Ltd. | 100.00 | 1 | ['customer', 'supplier'] |
| LMT | Lockheed Martin Corporation | 100.00 | 2 | |
| XAIR | Beyond Air, Inc. | 100.00 | 1 | ['customer'] |
| ABT | Abbott Laboratories | 100.00 | 1 | ['customer', 'supplier'] |
| ELDN | Eledon Pharmaceuticals, Inc. | 100.00 | 2 | |
| HON | Honeywell International Inc. | 100.00 | 2 | |
| CGC | Canopy Growth Corporation | 100.00 | 2 | |
| SVRE | SaverOne 2014 Ltd. | 100.00 | 2 | |
| NCEL | NewcelX Ltd. | 100.00 | 1 | ['supplier'] |
| NOC | Northrop Grumman Corporation | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 1 | ['customer', 'supplier'] |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| GILT | Gilat Satellite Networks Ltd. | 100.00 | 2 | |
| BWAY | BrainsWay Ltd. | 100.00 | 2 | |
| ALAR | Alarum Technologies Ltd. | 100.00 | 1 | ['customer'] |
| ALVO | Alvotech | 50.00 | 2 | |
| AKAM | Akamai Technologies, Inc. | 50.00 | 2 |